相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Reversal, maintenance or progression: What happens to the liver after a virologic cure of hepatitis C?
Youngmin A. Lee et al.
ANTIVIRAL RESEARCH (2014)
Ledipasvir: a novel synthetic antiviral for the treatment of HCV infection
Ivan Gentile et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2014)
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
Ivan Gentile et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2014)
Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection
Gregory T. Everson et al.
GASTROENTEROLOGY (2014)
Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial
Stefan Zeuzem et al.
GASTROENTEROLOGY (2014)
Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial
Xavier Forns et al.
GASTROENTEROLOGY (2014)
Expanded Classification of Hepatitis C Virus Into 7 Genotypes and 67 Subtypes: Updated Criteria and Genotype Assignment Web Resource
Donald B. Smith et al.
HEPATOLOGY (2014)
Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection
Hiromitsu Kumada et al.
HEPATOLOGY (2014)
Simeprevir with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial
Norio Hayashi et al.
JOURNAL OF HEPATOLOGY (2014)
Discovery and Early Clinical Evaluation of BMS-605339, a Potent and Orally Efficacious Tripeptidic Acylsulfonamide NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection
Paul M. Scola et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
The Discovery of Asunaprevir (BMS-650032), An Orally Efficacious NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection
Paul M. Scola et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
Stefan Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Peg-Interferon Plus Ribavirin with or without Boceprevir or Telaprevir for HCV Genotype 1: A Meta-Analysis on the Role of Response Predictors
Nicola Coppola et al.
PLOS ONE (2014)
Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential
Catherine Stedman
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2014)
Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection
Ivan Gentile et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2014)
Evolution of cell culture systems for HCV
Deborah R. Taylor
ANTIVIRAL THERAPY (2013)
Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C
Jean-Pierre Bronowicki et al.
ANTIVIRAL THERAPY (2013)
Emerging treatments for hepatitis C
Robert Flisiak et al.
EXPERT OPINION ON EMERGING DRUGS (2013)
Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection
David Alan Herbst et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
Once-Daily Simeprevir (TMC435) With Pegylated Interferon and Ribavirin in Treatment-Naive Genotype 1 Hepatitis C: The Randomized PILLAR Study
Michael W. Fried et al.
HEPATOLOGY (2013)
Postoperative Peg-Interferon Plus Ribavirin Is Associated With Reduced Recurrence of Hepatitis C Virus-Related Hepatocellular Carcinoma
Yao-Chun Hsu et al.
HEPATOLOGY (2013)
Resistance Analysis of Hepatitis C Virus Genotype 1 Prior Treatment Null Responders Receiving Daclatasvir and Asunaprevir
Fiona McPhee et al.
HEPATOLOGY (2013)
Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics A Randomized Clinical Trial
Anuoluwapo Osinusi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Dermatological side-effects of telaprevir-based triple therapy for chronic hepatitis C in phase III trials in Japan
Hideshi Torii et al.
JOURNAL OF DERMATOLOGY (2013)
Current prospects for interferon-free treatment of hepatitis C in 2012
Catherine A. M. Stedman
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2013)
Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir
Yoshiyasu Karino et al.
JOURNAL OF HEPATOLOGY (2013)
Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naive patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial
Maribel Rodriguez-Torres et al.
JOURNAL OF HEPATOLOGY (2013)
Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management
Jan Peveling-Oberhag et al.
JOURNAL OF HEPATOLOGY (2013)
Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options
Yoshiyuki Suzuki et al.
JOURNAL OF HEPATOLOGY (2013)
Perspectives and challenges of interferon-free therapy for chronic hepatitis C
Christian M. Lange et al.
JOURNAL OF HEPATOLOGY (2013)
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
Eric Lawitz et al.
LANCET INFECTIOUS DISEASES (2013)
National Antiviral Treatment Program and the Incidence of Hepatocellular Carcinoma and Associated Mortality in Taiwan
Chia-Hsuin Chang et al.
MEDICAL CARE (2013)
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Ira M. Jacobson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
Edward J. Gane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Profile of alisporivir and its potential in the treatment of hepatitis C
Philippe A. Gallay et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2013)
Prediction of sustained virologic responses to combination therapy of pegylated interferon-alpha and ribavirin in patients with chronic hepatitis C infection
Mona H. Ismail
JOURNAL OF FAMILY AND COMMUNITY MEDICINE (2013)
Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)
Fiona McPhee et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Single- and Multiple-Ascending-Dose Studies of the NS3 Protease Inhibitor Asunaprevir in Subjects with or without Chronic Hepatitis C
Claudio Pasquinelli et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Resistance Analysis of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir
Fiona McPhee et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets
Alexander Ploss et al.
GUT (2012)
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders
Kazuaki Chayama et al.
HEPATOLOGY (2012)
Antiviral strategies in hepatitis C virus infection
Christoph Sarrazin et al.
JOURNAL OF HEPATOLOGY (2012)
Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
Anna S. Lok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt
William Sievert et al.
LIVER INTERNATIONAL (2011)
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
Fred Poordad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection
Kenneth E. Sherman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
Bruce R. Bacon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Telaprevir for Retreatment of HCV Infection
Stefan Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Ira M. Jacobson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Hepatitis C Virus Non-structural Protein 3 (HCV NS3): A Multifunctional Antiviral Target
Kevin D. Raney et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Hepatitis C virus hijacks host lipid metabolism
Gulam H. Syed et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2010)
Critical Role of Cyclophilin A and Its Prolyl-Peptidyl Isomerase Activity in the Structure and Function of the Hepatitis C Virus Replication Complex
Zhe Liu et al.
JOURNAL OF VIROLOGY (2009)
Hepatitis C virus NS2 is a protease stimulated by cofactor domains in NS3
V. Schregel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Pegylated Interferon-α-2a plus Ribavirin for Treatment-Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial
Chen-Hua Liu et al.
CLINICAL INFECTIOUS DISEASES (2008)
Hepatitis C genotype 4: What we know and what we don't yet know
Sanaa M. Kamal et al.
HEPATOLOGY (2008)
A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C
Ming-Lung Yu et al.
GUT (2007)
A randomized trial of 24- vs. 48-week courses of PEG interferon α-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients:: a pilot study in Taiwan
ML Yu et al.
LIVER INTERNATIONAL (2006)
Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA
CL Jopling et al.
SCIENCE (2005)
Global epidemiology of hepatitis C virus infection
CW Shepard et al.
LANCET INFECTIOUS DISEASES (2005)
Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients
H Hinrichsen et al.
GASTROENTEROLOGY (2004)
An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus
D Lamarre et al.
NATURE (2003)
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
MW Fried et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
分享论文
